Pharmacological Activities of Calcium Antagonists: Therapeutic Applications and Adverse Reactions

  • P. A. van Zwieten
Conference paper

Abstract

Calcium antagonists or calcium entry blockers are considered to be a breakthrough in the drug treatment of cardiovascular disease, while their importance as tools in fundamental research is generally recognized as well. More recently, certain types of calcium antagonists have been studied as potentially useful drugs in the treatment of neurological disorders, such as migraine, cerebral ischemia and hypoxia, certain forms of vertigo, epilepsy, and subarachnoid hemorrhage.

Keywords

Ischemia Serotonin Neurol Catecholamine Propranolol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Betz E, Deck K, Hoffmeister F (eds) (1985) Nimodipine. Pharmacological and clinical properties. Proceedings of the 1st International Nimotop-Symposium, Munich 1984. Schattauer, StuttgartGoogle Scholar
  2. 2.
    Boddeke HWGM, Heynis JB, Jonkman FAM, Van Zwieten PA (1986) Characterization of calcium entry blockers in isolated guinea-pig hearts; cardiodepressant activity of flunarizine. Br J Pharmacol 89:615Google Scholar
  3. 3.
    Bou J, Llenas J, Massingham R (1983) Calcium entry blocking drugs, “calcium antagonists” and vascular smooth muscle function. J Auton Pharmacol 3:219–232PubMedCrossRefGoogle Scholar
  4. 4.
    Borgers M. Personal communicationGoogle Scholar
  5. 5.
    Braunwald E (1982) Mechanism of action of calcium channel blocking agents. N Engl J Med 307:1618–1627PubMedCrossRefGoogle Scholar
  6. 6.
    Bussey HF, Talbert RL (1984) Promising uses of calcium channel blocking agents. Pharmacotherapy 4:137–143PubMedGoogle Scholar
  7. 7.
    Fleckenstein A (1977) Specific pharmacology of calcium in the myocardium cardiac pacemaker and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17:149–166CrossRefGoogle Scholar
  8. 8.
    Fleckenstein A (1983) Calcium antagonism in heart and smooth muscle. Experimental facts and therapeutic prospects. Wiley, New YorkGoogle Scholar
  9. 9.
    Gelmers HJ (1984) The effects of nimodipine on the clinical course of patients with acute ischeemic stroke. Acta Neurol Scand 69:232–239PubMedCrossRefGoogle Scholar
  10. 10.
    Glossmann H, Ferry DR, Lubbecke F, Mewes R, Hofmann F (1982) Calcium channels: direct identification with radioligand binding studies. Trends Pharmacol Sci 3:431–437CrossRefGoogle Scholar
  11. 11.
    Glossmann H, Goll A, Rombusch M, Ferry DR (1985) Molecular pharmacology of Ca2+-channels: receptor binding studies. In: Betz A, Deck K, Hoffmeister A (eds) Nimodipine; pharmacological and clinical properties. Schattauer, Stuttgart, pp 57–76Google Scholar
  12. 12.
    Godfraind T, Miller RC, Socrates Lima J (1982) Selective α1 and α2-adrenoceptor agonist-induced contractions and 45Ca-fluxes in the rat isolated aorta. Br J Pharmacol 77:597–604PubMedGoogle Scholar
  13. 13.
    Godfraind T, Herman A, Wellens H (1984) Calcium entry blockers in cardiovascular and cerebral dysfunctions. Nijhoff, Den HaagCrossRefGoogle Scholar
  14. 14.
    Gray Ellrodt A, Singgh BN (1983) Clinical applications of slow channel blocking compounds. Clin Pharmacol Ther 23:1–43Google Scholar
  15. 15.
    Hartmann A, Van Zwieten PA (1986) Pharmacological aspects and neurological potential of calcium entry blockers. XIIIth World Congress of Neurology, Hamburg 1985. Eur Neurol 25(Suppl 1):1–126Google Scholar
  16. 16.
    Jonkman FAM, Boddeke HWGM, Van Zwieten PA (1986) Protective activity of calcium entry blockers against ouabain intoxication in anaesthetized guinea pigs. J Cardiovasc Pharmacol 8:1009–1013PubMedCrossRefGoogle Scholar
  17. 17.
    Kazda SR (1982) Nimodipine: a new calcium antagonistic drug with a preferential cerebrovascular action. Acta Neurochir 63:259–265CrossRefGoogle Scholar
  18. 18.
    Labrid C, Grosset A, Dureng G, Mironneau J, Duchêne-Marillaz P (1979) Some membrane interactions with bepridil, a new antianginal agent. J Pharmacol Exp Ther 211:546–554PubMedGoogle Scholar
  19. 19.
    Lederballe Pedersen O, Christensen NJ, Ramsch KD (1980) Comparison of acute effects of nifedipine in normotensive and hypertensive man. J Cardiovasc Pharmacol 2:357–361CrossRefGoogle Scholar
  20. 20.
    Mannhold R, Rodenkirchen R, Bayer R (1982) Qualitative and quantitative structure-activity relationships of specific Ca-antagonists. Prog Pharmacol 5:25–52Google Scholar
  21. 21.
    Marshall RJ, Winslow E, Lamar JC, Apoil E (1984) Bepridil. In: Scriabine A (ed) New drugs annuals: cardiovascular drugs, vol 2. Raven, New York, pp 157–176Google Scholar
  22. 22.
    Van Meel JCA, De Jonge A, Wilffert B, Kalkman HO, Timmermans PBMWM, Van Zwieten PA (1981) Organic and inorganic calcium antagonists reduce vasoconstriction in vivo mediated by postsynaptic α2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 316:288–293PubMedCrossRefGoogle Scholar
  23. 23.
    Van Meel JCA, Towart R, Timmermans PBMWM, Van Zwieten PA (1983) Correlation between the inhibitory activities of calcium antagonists on vascular smooth muscle constriction in vitro after depolarisation and in vivo after α2-adrenoceptor stimulation. Naunyn Schmiedebergs Arch Pharmacol 322:34–37PubMedCrossRefGoogle Scholar
  24. 24.
    Nayler WG, Poole-Wilson P (1981) Calcium antagonists: definition and mode of action. Basic Res Cardiol 76:1–15PubMedCrossRefGoogle Scholar
  25. 25.
    Nayler WG (1980) Calcium antagonists. Eur Heart J 1:225–237PubMedGoogle Scholar
  26. 26.
    Van Nueten JM, Janssen PAJ (1973) Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues. Arch Int Pharmacodyn Ther 204:37–55PubMedGoogle Scholar
  27. 27.
    Van Nueten JM, Van Beek J, Janssen PAJ (1978) Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch Int Pharmacodyn Ther 232:42–52PubMedGoogle Scholar
  28. 28.
    Van Nueten JM, Vanhoutte PM (1982) Calcium entry blockers and vasospasm. In: Vanhoutte PM, Leusen I (eds) Vasodilatation. Raven, New York, pp 459–468Google Scholar
  29. 29.
    Overweg J, Ashton D, De Beukelaar F, Binnie CD, Wauquier A, Van Wieringen A (1986) Add-on therapy in epilepsy with calcium entry blockers. Eur J Neurol 25:93–101Google Scholar
  30. 30.
    Paci A, Ottaviono B, Trenta A, Iannone G, Acuto G, Carosi M. Treatment of acute ischemic cerebral infarction with nimodipine (BAY e 9736). Cited in ref. 47Google Scholar
  31. 31.
    Packer M, Frishman WH (1984) Calcium channel antagonists in cardiovascular disease. Appleton-Century-Crofts, Norwalk (Conn), pp 225–269Google Scholar
  32. 32.
    Paoletti R, Vanhoutte PM (1987) International symposium on calcium antagonists. Pharmacology and clinical research. New York CityGoogle Scholar
  33. 33.
    Peters T (1983) “Calcium-Antagonismus”. Ein einheitlicher Begriff für uneinheitliche Wirkmechanismen. Med Klinik 78:368–375Google Scholar
  34. 34.
    Peters T (1986) Calcium in physiological and pathophysiological cell function. Eur Neurol 25(Suppl l):27–44PubMedCrossRefGoogle Scholar
  35. 35.
    Rodenkirchen R, Bayer R, Mannhold R (1982) Specific and nonspecific analysis of cardiodepressive drugs. Prog Pharmacol 5:9–23Google Scholar
  36. 36.
    Rodenkirchen R, Bayer R, Steiner R, Bossert F, Meyer H, Möller E (1979) Structure-activity studies on nifedipine in isolated cardiac muscle. Naunyn Schmiedebergs Arch Pharmacol 310:69–78PubMedCrossRefGoogle Scholar
  37. 37.
    Schwartz A, Triggle DJ (1984) Cellular action of calcium channel blocking drugs. Ann Rev Med 35:325–339PubMedCrossRefGoogle Scholar
  38. 38.
    Spedding M (1985) Calcium antagonist subgroups. Trends Pharmacol Sci 6:109–114CrossRefGoogle Scholar
  39. 39.
    Spedding M (1987) Three types of Ca2+-channels explain discrepancies. Trends Pharmacol Sci 8:115–117CrossRefGoogle Scholar
  40. 40.
    Tanaka K, Gotoh F, Muranratsu F et al. (1980) Effects of nimodipine (BAY e 9736) on cerebral circulation in cats. Arzneimittelforschung 26:2172–2176Google Scholar
  41. 41.
    Triggle DJ, Swamy VC (1983) Calcium antagonists. Some chemical-pharmacologic aspects. Circ Res 52(Suppl I): 17–28Google Scholar
  42. 42.
    Vanhoutte PM, Bohr DF (1981) Calcium entry blockers and the cardiovascular system. Fed Proc 40:2851Google Scholar
  43. 43.
    Wauquier A, Edmonds HC, Van den Broek WAE, Melis W, Van Loon J (1985) Effects of flunarizine on recovery of cerebral function following cardiac arrest. Neuropsychobiology 13:147–151PubMedCrossRefGoogle Scholar
  44. 44.
    Van Zwieten PA (1985) Calcium antagonists — terminology, classification and comparison. Arzneimittelforschung 35:298–301PubMedGoogle Scholar
  45. 45.
    Van Zwieten PA (1986) Differentiation of calcium entry blockers into calcium channel blockers and calcium overload blockers. Eur Neurol 25(Suppl 1):57–67PubMedCrossRefGoogle Scholar
  46. 46.
    Van Zwieten PA (1985) Drug targets in unstable angina. In: Hugenholtz PG, Goldman BS (eds) Unstable angina, current concepts and management. Schattauer, Stuttgart, pp 151–157Google Scholar
  47. 47.
    Van Zwieten PA, Timmermans PBMWM (1985) Pharmacological basis of the antihypertensive action of calcium entry blockers. J Cardiovasc Pharmacol 7:S11–S17PubMedCrossRefGoogle Scholar
  48. 48.
    Van Zwieten PA, Schönbaum E (1983) Calcium antagonists and blood vessels. Prog Pharmacol 5:1–142Google Scholar
  49. 49.
    Van Zwieten PA, Van Meel JCA, Timmermans PBMWM (1983) Pharmacological basis of the therapeutic effect of calcium entry blockers. Interaction with vascular α-adrenoceptors. Hypertension 5(Suppl II):II–8–II–17Google Scholar
  50. 50.
    Van Zwieten PA, Timmermans PBMWM, Van Heiningen PNM (1987) Receptor subtypes involved in the action of calcium antagonists. J Cardiovasc Pharmacol 5(Suppl 4):S21–S28Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • P. A. van Zwieten
    • 1
  1. 1.Division of Pharmacotherapy, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations